Bilkent University UNAM (National Nanotechnology Research Center) hosted the Advanced Cancer Biotherapeutics Symposium (ACTS ’24) on October 4-5, 2024. This symposium brought together clinicians, academics, graduate students, and industry partners to explore cutting-edge technologies and therapies in cancer treatment.
ACTS ’24 marked the beginning of an annual platform aimed at sharing knowledge and fostering collaborations in the field of cancer biotherapeutics. The inaugural event gathered leading experts to discuss the latest advancements in cancer treatment, setting the stage for future symposiums dedicated to this vital area of research.
The event featured a series of insightful presentations from leading experts in cancer biotherapeutics. Prof. Roman Jerala from the National Institute of Chemistry in Slovenia shared his expertise in cellular therapies, providing valuable insights into the latest advancements in synthetic biology and immunology. Prof. Fatih Ezgü from Gazi University’s Faculty of Medicine presented groundbreaking research on gene and cellular therapies, while Prof. Tarkan Karakan, also from Gazi University, discussed the implications of gastroenterology for cancer treatment. Prof. Tunca Doğan from Hacettepe University introduced bioinformatic approaches in cancer treatment, focusing on computational strategies to advance therapeutic development. The symposium also highlighted innovative research in antibody engineering by Assoc. Prof. Sibel Kalyoncu from the Izmir Biomedicine and Genome Center (IBG), as well as the cutting-edge work in cytokine and antibody engineering shared by Assoc. Prof. Li Tang from the Institute of Bioengineering at École Polytechnique Fédérale de Lausanne. Assoc. Prof. Tamer Önder from Koç University’s Research Center for Translational Medicine provided his expertise on cellular therapies and their applications in combating cancer. Lastly, Asst. Prof. Urartu Şeker from Bilkent University UNAM presented his pioneering work in antibody and cellular engineering, exploring new frontiers in cancer treatment.
The two-day event was packed with keynote lectures, invited talks, lightning presentations, and networking opportunities. The success of this inaugural symposium has laid a strong foundation for future gatherings that will continue to drive forward the field of cancer biotherapeutics.
